Marinus Pharmaceuticals Inc (NASDAQ:MRNS) is moving into a development contract with the Biomedical Advanced Research and Development Authority (BARDA). The company reveals that the contract will span about five years as the agreement’s terms stipulate it. The two parties will be focusing on developing IV ganaxolone, which is a product targeting the treatment of refractory status epilepticus (RSE).
Refractory status epilepticus (RSE) becomes life-threatening
The condition mentioned earlier is one of the many life-threatening illnesses that have forced many people to live in dire frustration. Experts say that the condition usually affects patients’ responses to the first- and second-line anticonvulsant drugs.
Several reasons have been cited as the causes for RSE. Part of those includes exposure to the nerve agents and some wide-ranging acute medical conditions. It is an agreement that will set to cover a base period, in which case BARDA will be entrusted with the provision of the subject matter expertise. Asides from that, it will also produce $21 million that will be channeled towards supporting the Phase 3 clinical trial of ganaxolone.
The role of BARDA
BARDA will also finance the preclinical studies of ganaxolone in line with what the experts refer to as the animal models’ nerve agent exposure. The Chief Executive Officer of Marinus Scott Braunstein has spoken on behalf of the company’s team, expressing their gratitude to BARDA for their cooperation.
The collaborative approach in the process has been deemed to be a progrment of the companies’ set goals. The two companies hope to succeed in their quest to develop leading innovations in the seizure disorders segment.
At the same time, they will be hoping to do a great job in line with showcasing support for the efforts being made by the government to protect the lives of US citizens. There will always be the fear of a chemical attack, and thus great need to guard lives.
The Marigold Study was a major step forward for Marinus Pharmaceuticals, and the company is pleased to pronounce its positive top-line results. That study sought to undertake an evaluation of oral ganaxolone in among the young adults and children with CDKL5 deficiency disorder (CDD).
